News | November 16, 2024
Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Construction of the plant will commence in 2025 with first production expected to be in 2027
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
Subscribe To Our Newsletter & Stay Updated
